Who we are?

We are Juyoung Bio, We believe
Biology is Programmable & We can guide the Code..

We're not betting on or relying on one drug. We're building a scalable platform that integrates into lives.

Our generative AI reduces discovery to months, predicts toxicity early, and cuts costs by up to 50%.

  • Biology-tuned Large Language Models (LLMs)
  • Structure-aware Graph Neural Networks (GNNs)
  • AlphaFold-based molecular modeling
Prof. Kil To Chong
Prof. Kil To Chong CEO
Juyoung Bio, South Korea Scholars GPS Top 0.05% Researcher Worldwide Publications → Platforms → Real Drug Candidates kitchong@jbnu.ac.kr (82) 10-3675-2004

The Challenge

Over 90% of drug candidates fail in Phase I/II, primarily due to poor target validation and late detection of toxicity — the "Valley of Death."

Our Solution

De-risking drug discovery with AI-validated biology. We translate AI insights into experimentally validated, decision-ready drug candidates.

Validated in Practice

  • Validated 3 hit candidates with >90% binding affinity in wet-lab assays
  • An AI-driven antimicrobial peptide pipeline

The AI Drug Discovery market is projected to reach $50B by 2028.

Trajectory of Juyoung Bio

starts with a clear goal, then defines the most direct path

Juyoung Bio: Strategic Growth Trajectory (2021–2030)

Swipe to view full timeline →

Corporate Value / TRL Timeline (2021-2030) 2021 2023 2024 2025 2026 2028 2030 Phase 1: Foundation & R&D (The Valley) The Pivot Point Global Partnership & Pilot Phase Phase 3: Hyper-Growth Company Founding Incubation @ JBNU Validation Series A Clinical Entry Licensing & Revenue IPO / M&A Target

Juyoung Bio leading – Drug discovery pipeline

INDICATION TARGET ID HIT-TO-LEAD LEAD OPT IND-ENABLING PHASE I PHASE II
Antimicrobial Peptides (AMPs) Potent bactericidal activity against (MDR) pathogens. JYB-AMP-101
JAK2 Inhibitor (Blood Cancer – MPNs, MF & PV) Bioavailable JAK2 inhibitors with strong efficacy and safety. JYB-JKI-765
Peptide for TNBC Targeting HIF-1/CBP Complex. JYB-HCBP-971
Tropical Chagas Disease – Cruzipain Inhibitors Inhibitors for neglected tropical disease. JYB-CRI-543
Novel Antihypertensive Compounds Natural antihypertensive agents with strong potency. JYB-HY-X43
Acute Stroke Treatment Candidates for acute stroke treatment. JYB-HS-X7B
Novel small molecules for Lung Cancer MAPK3 inhibitor. JYB-KI-2ZK
Novel compound for NSCLC Allosteric EGFR mutant inhibitor overcoming TKI resistance. JYB-EGKI-4XM
Available for licensing More programs in discovery

Juyoung Bio

Software as a Service

PUResNet

PUResNet

Rapid binding-site prediction for scalable small-molecule drug discovery

NanoBinder

NanoBinder

Fast nanobody screening for biologics and antibody drug development

Nanobody Design

Nanobody Design

AI-designed nanobodies for next-generation biologic therapeutics

PTMGPT2

PTMGPT2

Explainable AI for PTM-driven cancer diagnosis and target discovery

SARS-Escape AI

SARS-Escape AI Platform

AI prediction of immune-evasive SARS-CoV-2 spike mutations

End-to-End AI Drug Discovery

End-to-End AI Drug Discovery Platform

One AI platform delivering multiple drug candidates efficiently

Key Partners

Partner
Partner
Partner
Partner
Partner
Partner
Partner
Partner
Partner
Partner
Partner

IP & Tech Portfolio

Patented

RNA splicing branch point selection system based on deep learning model

An alternative splicing prediction system using a deep learning model based on distributed feature representation

Method and system for predicting protein-ligand binding sites using deep residual neural networks

Method and system for predicting the correlation between miRNA and small molecules using recurrent neural networks

Method and system for identifying epigenetic modifications

Patent Applied

Method and system for predicting N4-methylcytosine modification

RNA splicing branch point selection system based on a deep learning model

A novel antimicrobial agent identification method and program using a semi-supervised variational autoencoder

An AI-based JAK2 inhibitor screening method and novel JAK2 inhibitor compounds